a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with ENTO. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then ENTO could also see price increases.
Ticker / NAME | Correlation To RLMD | 1D Price Change % | ||
---|---|---|---|---|
RLMD | 100% | -2.73% | ||
ENTO - RLMD | 36% Loosely correlated | +1.61% | ||
ARGNF - RLMD | 31% Poorly correlated | N/A | ||
CABA - RLMD | 30% Poorly correlated | -6.74% | ||
ATXS - RLMD | 28% Poorly correlated | -4.93% | ||
CYTK - RLMD | 27% Poorly correlated | -0.41% | ||
More |